For these patients, the benefits are particularly valuable
To explore insured impacts further, and how they may translate to your policyholders, reach out to your local RGA representative
GLP-1RA Liraglutide Semaglutide Efpeglenatide Glucose lowering effect CV system protection effect Kidney protection effect Nonalcoholic fatty liver disease GIP/GLP1 receptor coagonists: tirzepatide Amylin/GLP1 receptor coagonists: CagriSema (cagrilintide+semaglutide) Glucagon/GLP1 receptor coagonists: survodutide GIP/GLP1/glucagon receptor triple coagonists: retatrutide Obesity is a disease that can be treated with targeted pharmacotherapy in addition to lifestyle modification and behavioral interventions
Doses cant be guaranteed, and they may be mixed with other ingredients that may lead to adverse effects, Isaacs says
Prior to GLP-1 indication expansions into this therapy area, a similar trend appeared among patients with MASLDa condition where evidence increasingly supports therapeutic benefit 4
Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: a 24 months follow-up study
